ArticleIranian journal of pharmaceutical research : IJPR
Gamabufotalin Suppresses Colorectal Cancer Growth via Oxidative Stress-Induced Apoptosis and DNA Synthesis Inhibition.
Article in Iranian journal of pharmaceutical research : IJPR. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Colorectal cancer (CRC) continues to be a major cause of cancer-related mortality worldwide, creating an urgent need to develop novel therapeutic agents that are both highly effective and minimally toxic. Gamabufotalin (GA), a bioactive bufadienolide compound, has shown promising antitumor potential, including against CRC; however, its precise mechanisms of action in CRC remain incompletely understood. Objectives: The aim of this study was to investigate the therapeutic effect of GA on CRC and explore the underlying molecular mechanisms. Methods: A combination of in vitro and in vivo approaches was employed, including cell viability assays, colony formation, EdU incorporation, cell cycle and apoptosis analyses by flow cytometry, ROS and mitochondrial membrane potential detection, as well as integrated transcriptomic and proteomic profiling. The in vivo antitumor efficacy was further validated in a nude mouse xenograft model. Results: Gamabufotalin exhibited potent, dose-dependent anti-CRC activity in vitro (IC Conclusions: Gamabufotalin selectively and potently inhibits CRC through dual mechanisms: Inducing ROS-mediated apoptosis and suppressing proliferation. With a favorable therapeutic index and defined molecular targets, GA represents a promising candidate for CRC therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.